Aktieselskabet Schouw & Co. (CPH:SCHO)
Denmark · Delayed Price · Currency is DKK | Market Cap | 19.86B +51.0% |
| Revenue (ttm) | 35.79B +4.7% |
| Net Income | 962.00M +4.3% |
| EPS | 42.38 +5.6% |
| Shares Out | 22.39M |
| PE Ratio | 20.93 |
| Forward PE | 13.37 |
| Dividend | 17.00 (1.92%) |
| Ex-Dividend Date | Apr 17, 2026 |
| Volume | 6,959 |
| Open | 893.00 |
| Previous Close | 889.00 |
| Day's Range | 883.00 - 894.00 |
| 52-Week Range | 565.00 - 895.00 |
| Beta | 0.78 |
| Analysts | Strong Buy |
| Price Target | 971.67 (+9.55%) |
| Earnings Date | Nov 6, 2026 |
About CPH:SCHO
Aktieselskabet Schouw & Co., an industrial conglomerate, manufactures feed for the fish and shrimp farming industries in Norway, Denmark, the United Kingdom, the rest of Europe, Chile, the United States, the rest of Americas, Asia, Oceania, and Africa. It operates in six segments: BioMar, GPV, HydraSpecma, Borg Automotive, Fibertex Personal Care, and Fibertex Nonwovens. The BioMar segment offers feed products for salmon, trout, shrimp, sea bass, and sea bream in the fish and shrimp farming industries. The GPV segment manufactures electronics, m... [Read more]
Financial Performance
In 2025, CPH:SCHO's revenue was 34.13 billion, a decrease of -1.55% compared to the previous year's 34.67 billion. Earnings were 650.00 million, a decrease of -31.58%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for SCHO stock is "Strong Buy." The 12-month stock price target is kr 971.67, which is an increase of 9.55% from the latest price.
News
Aktieselskabet Schouw & Co. Earnings Call Transcript: Q3 2026
Q3 revenue rose 16% and EBITDA 37%, with broad-based gains and lower net debt. Strong backlogs drove higher FY guidance, while selected component supply and Asian market pressures remain watchpoints.
Aktieselskabet Schouw & Co. Quarterly report: Q3 2026
Aktieselskabet Schouw & Co. has published its Q3 2026 quarterly earnings report on November 6, 2026.
Aktieselskabet Schouw & Co. Slides: Q3 2026
Aktieselskabet Schouw & Co. has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 6, 2026.
Aktieselskabet Schouw & Co. Transcript: CMD 2026 presentation
Expand 2030 targets 5%–7% annual organic growth and DKK 4.5bn EBITDA by 2030. Spectre and GPV outlined growth plans, while BioMar IPO proceeds strengthened financial flexibility and portfolio transparency.
Aktieselskabet Schouw & Co. Slides: FY 2026
Aktieselskabet Schouw & Co. has posted slides in relation to its FY 2026 quarterly earnings report, which was published on October 8, 2026.
Aktieselskabet Schouw & Co. Earnings Call Transcript: Q2 2026
Raised group revenue and EBITDA guidance for 2026, with all major subsidiaries showing improved profitability and several raising their own outlooks. Operational efficiency, new product launches, and strategic acquisitions supported growth, while supply chain and raw material risks remain.
Aktieselskabet Schouw & Co. Quarterly report: Q2 2026
Aktieselskabet Schouw & Co. has published its Q2 2026 quarterly earnings report on August 14, 2026.
Aktieselskabet Schouw & Co. Slides: Q2 2026
Aktieselskabet Schouw & Co. has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 14, 2026.
Aktieselskabet Schouw & Co. Earnings Call Transcript: Q1 2026
Q1 2026 delivered EBITDA and EBT growth despite a 3% revenue decline, with strong operational execution and deleveraging. Segment performance was mixed, but guidance for the full year is maintained, and the BioMar IPO process has advanced.
Aktieselskabet Schouw & Co. Quarterly report: Q1 2026
Aktieselskabet Schouw & Co. has published its Q1 2026 quarterly earnings report on May 1, 2026.
Aktieselskabet Schouw & Co. Slides: Q1 2026
Aktieselskabet Schouw & Co. has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 1, 2026.
Aktieselskabet Schouw & Co. Earnings Call Transcript: Q4 2025
Revenue and EBITDA declined slightly due to raw material and Forex headwinds, but cash flow hit a record high and leverage improved. Most segments delivered EBITDA growth, with strong guidance for 2026 and continued focus on capital discipline and efficiency.
Aktieselskabet Schouw & Co. Annual report: Q4 2025
Aktieselskabet Schouw & Co. has published its Q4 2025 annual report on March 5, 2026.
Aktieselskabet Schouw & Co. Slides: Q4 2025
Aktieselskabet Schouw & Co. has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 5, 2026.
Aktieselskabet Schouw & Co. Earnings Call Transcript: Q3 2025
Q3 saw a 4% revenue decline but a 5% EBITDA increase, driven by strong cost control and margin management. BioMar delivered record EBITDA despite biological headwinds, while other segments showed mixed results amid ongoing market uncertainties.
Aktieselskabet Schouw & Co. Quarterly report: Q3 2025
Aktieselskabet Schouw & Co. has published its Q3 2025 quarterly earnings report on November 12, 2025.
Aktieselskabet Schouw & Co. Slides: Q3 2025
Aktieselskabet Schouw & Co. has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 12, 2025.